Propentofylline: glial modulation, neuroprotection, and alleviation of chronic pain.
Propentofylline is a unique methylxanthine with clear cyclic AMP, phosphodiesterase, and adenosine actions, including enhanced synaptic adenosine signaling. Both in vitro and in vivo studies have demonstrated profound neuroprotective, antiproliferative, and anti-inflammatory effects of propentofylline. Propentofylline has shown efficacy in preclinical models of stroke, opioid tolerance, and acute and chronic pain. Clinically, propentofylline has shown efficacy in degenerative and vascular dementia, and as a potential adjuvant treatment for schizophrenia and multiple sclerosis. Possible mechanisms of action include a direct glial modulation to decrease a reactive phenotype, decrease glial production and release of damaging proinflammatory factors, and enhancement of astrocyte-mediated glutamate clearance. This chapter reviews the literature that supports a myriad of protective actions of this small molecule and implicates propentofylline as a potential therapeutic for the treatment of chronic pain. From these studies, we propose a CNS multipartite synaptic action of propentofylline that includes modulation of pre- and postsynaptic neurons, astrocytes, and microglia in the treatment of chronic pain syndromes, including, but not limited to, neuropathic pain.
Sweitzer
Sarah
S
Department of Pharmacology, University of South Carolina, USC School of Medicine, Columbia, SC 29208, USA.
De Leo
Joyce
J
D000818:Animals; D002908:Chronic Disease; D004361:Drug Tolerance; D006801:Humans; D009020:Morphine / Q000494:pharmacology; D009457:Neuroglia / Q000187:drug effects*; D018696:Neuroprotective Agents / Q000494:pharmacology*; D010146:Pain / Q000188:drug therapy*; D014970:Xanthines / Q000494:pharmacology* / Q000627:therapeutic use
D018696:Neuroprotective Agents; D014970:Xanthines; C032114:propentofylline; D009020:Morphine